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When used as a patient's first access, AVF survival was superior Background. A direct broad-based comparison of vascular to grafts regarding time to first failure (RR ϭ 0.53, P ϭ 0.0002), access use and survival in Europe (EUR) and the United States and AVF survival was longer in EUR compared with the US (US) has not been performed previously. Case series reports (RR ϭ 0.49, P ϭ 0.0005). AVF and grafts each displayed better suggest that vascular access practices differ substantially in the survival if used when initiating HD compared with being used US and EUR. We report on a representative study (DOPPS) after patients began dialysis with a catheter. which has used the same data collection protocol for Ͼ6400
Conclusion: Large differences in vascular access use exist hemodialysis (HD) patients to compare vascular access use at between EUR and the US, even after adjustment for patient 145 US dialysis units and 101 units in five EUR countries (France, Germany, Italy, Spain, and the United Kingdom).
characteristics. The results strongly suggest that a facility's prefMethods. Logistic analysis evaluated factors associated with erences and approaches to vascular access practice are major native arteriovenous fistula (AVF) versus graft use or permadeterminants of vascular access use. nent access versus catheter use for prevalent and incident HD patients. Times to failure for AVF and graft were analyzed using Cox proportional hazards regression.
Vascular access use is an integral and important aspect
Results. AVF was used by 80% of EUR and 24% of US prevof hemodialysis treatments provided for patients with alent patients, and was significantly associated with younger age, male gender, lower body mass index, non-diabetic status, end-stage renal disease (ESRD). Two types of permalack of peripheral vascular disease, and no angina. After adnent accesses are used in hemodialysis: (1) native arteriojusting for these factors, AVF versus graft use was still much venous fistulas (AVF) that are formed from a patient's higher in EUR than US (AOR ϭ 21, P Ͻ 0.0001). AVF use endogenous vasculature, and (2) grafts that are created within facilities varied from 0 to 87% (median 21%) in the US, and 39 to 100% (median 83%) in EUR. For patients who using either synthetic material or bovine vessels. For were new to HD, access use was: 66% AVF in EUR versus some practitioners, synthetic grafts are desired for ease 15% in US (AOR ϭ 39, P Ͻ 0.0001), 31% catheters in EUR of cannulation [1] , shorter maturation times, and usevs. 60% in US, and 2% grafts in EUR vs. 24% in US. In fulness when a patient's vascular anatomy does not afaddition, 25% of EUR and 46% of US incident patients did ford construction of an AVF. However, AVF are viewed not have a permanent access placed prior to starting HD. In EUR, 84% of new HD patients had seen a nephrologist for as being superior to grafts due to the much small number Ͼ30 days prior to ESRD compared with 74% in the US (P Ͻ of procedures associated with AVF use, and longer over-0.0001); pre-ESRD care was associated with increased odds of all survival [2] . Furthermore, initial results reported by AVF versus graft use (AOR ϭ 1.9, P ϭ 0.01). New HD patients Dhingra et al suggest a lower mortality risk for prevalent had a 1.8-fold greater odds (P ϭ 0.002) of starting HD with a permanent access if a facility's typical time from referral to diabetic patients when dialyzing with an AVF compared access placement was Յ2 weeks. AVF use when compared to to a graft (abstract; J Am Soc Nephrol 11:182A, 2000).
It has been reported that vascular access use among chronic hemodialysis (HD) patients differs between the (DOPPS) to examine vascular access use in the US and in which AVF are compared to grafts, synthetic grafts and bovine grafts were combined together to form the five European countries (France, Germany, Italy, Spain, and the United Kingdom). DOPPS is a prospective, lon-"graft" group. Bovine grafts comprised 3 to 4% of all grafts used by HD patients in the US and EUR. gitudinal study of hemodialysis practices and associated outcomes. Facilities and patients are selected to provide Description of cross-sectional and incident nationally representative samples of the HD population patient samples in each country as described previously [8] . The same data collection protocol is used in all countries allowing
The types of vascular access in use were described for the cross-section of all patients (prevalent) enrolled at a direct comparison of outcomes across countries and types of facilities.
the start of the study and for new (incident) HD patients enrolled anytime during the study. Patients were classiThe goals of the present investigation were to (1) compare the frequencies of vascular access types used by fied as incident patients if their study enrollment date was within five days of their first HD treatment for HD patients in the US and the five European countries, (2) examine patient and practice pattern characteristics ESRD. For the incident samples in the US and EUR, greater than 90% of patients were on dialysis for one that may influence vascular access use, (3) compare native arteriovenous fistula (AVF) and graft survival in day or less when entering DOPPS. Therefore, the access in use at study start for these patients is equivalent to the US and Europe, and (4) determine differences in placement of temporary vascular accesses for incident the access used for the patient's first HD treatment. patients in the US and Europe. failure among incident HD patients. Time to failure was calculated as the time from first use until first failure. United States data for this analysis were collected from July 1996 to October 2000, and data from EUR were gathFailure was defined as any reported event (such as thrombosis) that resulted in an access no longer able to function ered from July 1998 to October 2000. Nationally representative samples were obtained using randomized pafor HD, even though the access may be usable at a later time if successfully salvaged by subsequent declotting or tient selection with ongoing longitudinal data collection as described previously [8] .
Statistical analysis
revision procedures. Observations were censored when a patient departed from the facility or the last day of Vascular access data were collected for each patient at entry into the study and updated whenever a vascular known access follow-up. are attributable to factors other than the covariates. Graphic analyses confirmed the validity of the proportional hazards assumption. All statistical analyses were performed using SAS ver- 
RESULTS

Vascular access use among prevalent HD patients in EUR and the US
Demographic and comorbid characteristics at the time very similar to the values reported for the 1997 US population of in-center HD patients by the U.S. Renal Data of study entry are shown in Table 1 for a cross-sectional sample of HD patients in EUR and the US. The US was System [11]. Comparable information is not available for EUR from other published sources. significantly (P Ͻ 0.05) different from EUR with regard to all listed comorbid and demographic characteristics,
The pattern of vascular access use among prevalent HD patients revealed much greater utilization of AVF except for age (P ϭ 0.78). Because of these differences in patient mix between EUR and the US, these demoin EUR compared with the US (Table 2 ). In EUR, AVF accounted for 80% of all accesses, with 10% of patients graphic and comorbid characteristics were included as covariates in adjusted models of vascular access use.
using grafts. High AVF use was seen in all five EUR countries, ranging from 67% in the United Kingdom to 90% Differences between the US and EUR also were seen in the proportion of patients with hypertension, myocardial in Italy. In contrast, grafts were the predominant access type in the US, comprising 58% of all accesses, with 24% infarction, congestive heart failure, and chronic obstructive pulmonary disease, but these comorbidities were not of US patients using an AVF. Catheter use was 17% in the US compared with 8% in EUR (P Ͻ 0.0001). found to be significantly related to vascular access use among prevalent patients. The values for age, diabetes A logistic model was used to evaluate patient characteristics associated with AVF versus graft use in prevamellitus as primary cause of ESRD, and proportion of female and black patients in the US-DOPPS sample are lent HD patients in EUR and the US (Table 3 ). AVF use was found to be strongly related (P Ͻ 0.01) to younger versus graft use is associated with certain patient characteristics, but a large difference remains in AVF use beage, male gender, non-diabetic status, lower body mass index, no history of angina, and absence of peripheral tween the US and EUR that is not accounted for by differences in these patient characteristics. vascular disease (PVD). Although the probability of AVF use was not associated with the number of years Arteriovenous fistulae use among prevalent patients was also compared in EUR and the US for two patient of HD treatment when analyzed across all countries (AOR ϭ 0.99, P ϭ 0.18), a continent-specific analysis subgroups with different levels of associated comorbidity (Fig. 1) . The first subgroup consisted of non-diabetic indicated that years of HD treatment had opposite effects upon AVF use in EUR (AOR ϭ 0.93 for every patients, age 18 to 54 years old, without peripheral vascular disease and without coronary artery disease. In EUR, year of HD, P Ͻ 0.0001) compared with the US (AOR ϭ 1.02 for every year of HD, P ϭ 0.04). Allon et al recently 76% of females and 89% of males in this subgroup were using an AVF compared with 41% of US males and 22% showed AVF use for prevalent patients in the US HEMO study to be significantly related to these characteristics, of US females. The second subpopulation consisted of diabetic patients, Ͼ54 years of age, who have peripheral except angina, which was not tested [12] . The HEMO study also showed coronary artery disease to be signifivascular disease and/or coronary artery disease. AVF use was high for this group of patients in EUR, ranging cantly related to AVF use. Our analysis found that coronary artery disease (CAD) was significantly associated from 64% for females to 82% for males. However in the US, only 22% of males and 10% of females used an with AVF use if history of angina was excluded from the model (AOR ϭ 0.85, P ϭ 0.03), but CAD was not AVF in this group. The results of the subpopulation analysis demonstrate that the high level of AVF use in significant if angina was included in the model (AOR ϭ 0.96, P ϭ 0.63). Therefore, the effect of coronary artery EUR is seen both for patients of low or high comorbidity levels. AVF use in the US is substantially lower than disease on AVF use is explained by the angina variable in our analytical model. EUR, even for relatively young, non-diabetic patients without coronary artery disease. The above analysis model also indicated that the likelihood of AVF versus graft use was much greater in EUR
The percentage of AVF use in different dialysis units in each country was also determined (Fig. 2) . EUR dialthan in the US (AOR ϭ 21, P Ͻ 0.0001). Parameter estimates obtained from a similar logistic model reysis units displayed a range of AVF use, varying from 39% in some facilities to 100% in others, with a median stricted to EUR practice were applied to the US patient mix, and estimated that 79% of US patients would be facility value of 83% AVF use. In EUR, 31% of dialysis units had an AVF use rate of Ն90%, with 100% of expected to use an AVF if the EUR practice of access placement was applied to the US patient mix of age, patients using an AVF in 25% of Italian dialysis units. US dialysis units displayed rates as low as 0% AVF use gender, diabetes mellitus, peripheral vascular disease, body mass index, history of angina, and years on HD.
in some dialysis units but as high as 87% in other facilities, with a median facility value of 21% AVF use. These In conclusion, the analytical models indicate that AVF results indicate that despite a moderately low overall use an AVF when starting HD. In contrast, 60% of US inciof AVF in the US, some facilities have achieved a high dent patients began dialysis with a catheter, with only rate of AVF use comparable to that seen for many EUR 15% using an AVF and 24% using a graft. facilities. However, one-quarter of US dialysis units had Pre-ESRD care was compared between EUR and the very low AVF use in which only 0 to 12% of patients US to determine its effect upon access use at the start dialyzed with an AVF within each of these units. In the of HD ( proportion of EUR patients receiving long term pre-ESRD care, with 69% of EUR patients seeing a nephrolSimilar to the prevalent patient sample, large differogist for at least one year prior to ESRD compared with ences were seen in AVF use by new (incident) HD pa-44% in the US. tients in the US compared with EUR. AVF were used by Various relationships between early nephrologic care 66% of incident HD patients in EUR when starting HD, and the type of access used by incident patients when startwith 2% of EUR incident patients using a graft (Taing HD were examined. For patients receiving nephroble 2). In four of the five EUR countries, AVF use ranged logic care Ͼ30 days prior to ESRD, 79% of EUR patients from 60 to 83% among new HD patients, whereas in the United Kingdom 47% of incident patients dialyzed with and 48% of US patients (P Ͻ 0.0001) used a permanent access for their first HD treatment (data not shown). ripheral vascular disease, history of angina, pre-ESRD care Ͼ30 days prior to ESRD, time from referral to This result indicates that EUR pre-ESRD practice is substantially more successful than US pre-ESRD pracaccess creation, typical time until AVF are first cannulated, use of surgery trainees, or the number of surgeons tice in establishing a permanent access that is functional for a patient's first HD treatment, even though a large placing permanent vascular accesses for patients in a dialysis unit. proportion of EUR patients start HD with an AVF. Furthermore, 46% of US incident patients and 25% of Permanent access versus temporary access comparisons revealed that permanent vascular access use at start EUR incident patients did not have a permanent access placed prior to starting dialysis, even though 55% of of HD is greater in EUR than in the US (AOR ϭ 4.8, P Ͻ 0.0001) and is less likely for female patients (AOR ϭ these patients in both EUR and the US had seen a nephrologist Ͼ30 days prior to ESRD (data not shown).
0.82, P ϭ 0.05) or for patients having a history of angina (AOR ϭ 0.81, P ϭ 0.04; Table 5 ). In addition, permanent A logistic model was used to evaluate the relationships of various patient characteristics and treatment practices access use at the start of HD was substantially more likely if patients were treated in a dialysis unit that typiupon AVF versus graft use by new ESRD patients when starting HD (Table 5) . AVF use was significantly less cally creates an access within two weeks of referral (AOR ϭ 1.76, P ϭ 0.002) or if patients saw a nephrologist likely if patients were female (AOR ϭ 0.39, P Ͻ 0.0001) or if surgery trainees assisted or performed vascular ac-Ͼ30 days prior to ESRD (AOR ϭ 6.1, P Ͻ 0.0001). Subgroup analyses were used to explore access use in cess placements for the dialysis unit (AOR ϭ 0.61, P ϭ 0.04). Patient age, diabetes, peripheral vascular disease, EUR versus US further. Three different incident HD patient subpopulations were analyzed (Fig. 3) . The first history of angina, a facility's usual time from referral to access placement, a facility's typical time from AVF two groups were non-diabetic white males of (group i) age 18 to 54 years, or (group ii) age Ͼ54 years, and the creation until first cannulation, and number of surgeons were not significantly related to whether patients began third group was white diabetic females Ͼ17 years old (group iii). The race restriction was used to make com-HD with an AVF versus a graft. However, AVF use was substantially more likely than graft use if patients received parisons across continents more easily, and the relatively smaller number of patients in the diabetic female subnephrologic care Ͼ30 days prior to ESRD (AOR ϭ 1.95, P ϭ 0.01) or if treated in EUR compared to the US group limited further division of this subgroup into different age categories. The results of this analysis indicate (AOR ϭ 39, P Ͻ 0.0001). This latter result indicates that there continues to be a large difference in AVF versus that in the US, AVF use among the two incident male non-diabetic groups was 24% and 19%, respectively, and graft use among incident patients in EUR and US even after adjustment for age, gender, diabetes mellitus, pedecreased to 11% for incident female diabetic patients. were new to HD and using an AVF at study start was determined for the three groups. Values of n refer to the total number of patients in the particular subgroup.
In contrast, AVF use was high for all three groups in nantly accounted for by Italian nephrologists, who comprised 96% of all nephrologists placing accesses among EUR, ranging from 63% for diabetic females to 77% for non-diabetic males aged 18 to 54 years. incident patients in the study sample. In the above analysis, grafts accounted for Ͻ0.5% of Permanent vascular access survival in the all accesses among EUR non-diabetic males and 4% of US and EUR accesses among EUR diabetic females. In contrast for the US, 18% of non-diabetic males and 25% of diabetic Cox regression analyses adjusted for case-mix were females used grafts when starting HD. These results furused to assess AVF and graft survival among incident ther indicate that grafts are seldom used as the choice patients in EUR and the US. The AVF versus graft of a permanent access for incident patients in EUR, even survival in Figure 4A is for incident patients who used among diabetic female patients.
either a graft or AVF for their first HD treatment. The estimated one-year survival probability was 68% for Type of physician placing permanent vascular accesses AVF (95% CI 59 to 77%, N ϭ 177) and 49% for grafts (95% CI 42 to 57%, N ϭ 251) in the US, with AVF in Country variation was observed concerning the type of physician who generally places permanent vascular EUR displaying a one year survival of 83% (95% CI ϭ 78 to 89%, N ϭ 429). The case-mix adjusted survival accesses for HD patients. In France, Germany, Spain, the UK, and the US, 65 to 89% of permanent vascular curves indicated substantially better survival of AVFs compared with grafts in the US [risk ratios (RR) of accesses were placed by a vascular surgeon. However, in Italy, approximately 80% of permanent access placefailure ϭ 0.56, P ϭ 0.0009]. In addition, AVF survival was found to be greater in EUR than in the US (RR of ments were performed by a nephrologist, similar to the recent report by Bonucchi et al [6] . Logistic models of failure ϭ 0.49 in EUR versus US, P ϭ 0.0003). The small number of grafts placed among EUR incident patients AVF versus graft use at start of HD did not find a significant relationship between AVF use and the type of physiprecluded a survival analysis of grafts for EUR. Regarding other covariates tested in a model of AVF survival, cian placing the permanent vascular access with regard to vascular surgeons, general surgeons, transplant surgeons, peripheral vascular disease (RR ϭ 3.2, P ϭ 0.001) and female gender (RR ϭ 2.3, P ϭ 0.003) were associated or urologists (P value range, 0.48 to 0.55 depending on physician type, data not shown). However, if a nephrolowith increased risk of AVF failure in EUR, with peripheral vascular disease possibly related to increased AVF gist was the primary type of physician placing permanent vascular accesses for patients in a dialysis unit, then 100% failure also within the US (RR ϭ 1.7, P ϭ 0.12). Whereas the above analysis indicates better survival of incident patients who began HD with a permanent access were found to use an AVF in these units (N ϭ 74 of AVF compared with grafts for patients who start HD with a permanent access, the pattern of AVF versus graft patients). This latter practice of high AVF use associated with access placement by nephrologists was predomisurvival is more complex if patients use a temporary catheter for their first HD treatment and then the surwould each decrease by 3% points with no change in graft survival, resulting in a small increase of 6 to 7% in vival of a subsequently used AVF or graft is determined. In this situation, no significant difference was observed the risk ratios of failure for AVF versus grafts in the US, and AVF in EUR versus the US. in AVF versus graft survival in the US during the first 240 days of use (RR of failure ϭ 0.76, P ϭ 0.24), whereas
Sites of catheter placement after this time period AVF displayed substantially better long-term survival compared with grafts (Fig. 4B) .
The site where catheters were placed was compared for incident patients in EUR and the US (Fig. 5) . In Both in EUR and the US, AVF survival was substantially better when AVF were used for the first HD treat-EUR, the internal jugular vein was the most commonly used site, serving for 57% of untunneled catheters and ment compared with AVF first used after starting HD with a catheter (in EUR, RR of failure ϭ 0.50, P ϭ 80% of tunneled catheters. In addition, 15 to 18% of EUR catheters were placed in the subclavian vein. In 0.001; in US, RR of failure ϭ 0.63, P ϭ 0.03, if AVF was used for first HD treatment). In addition, graft survival in the US, the subclavian vein (46%) and internal jugular vein (46%) were the most commonly used sites for unthe US was better if used for the first HD treatment versus grafts used after starting HD with a catheter (RR tunneled catheters, with tunneled catheters placed predominantly in the internal jugular vein (62%) and the of failure ϭ 0.70, P ϭ 0.03).
For the above survival analyses, elective angioplasty subclavian vein (36%). Since DOPPS data collection in the US has occurred was not included as an indication of access failure. However, a sensitivity analysis demonstrated that if elective over the time period from 1996 through 2000, a time trend analysis was performed. It indicated that subclaangioplasty had been included as a failure, then the oneyear AVF survival probabilities in the US and EUR vian vein placement of catheters has decreased in the for the US are similar to those reported by Woods and Port [13] and Stehman-Breen et al [14] . A major question addressed during these analyses was what are the predominant factors associated with access use? Patient age, gender, diabetes, peripheral vascular disease, body mass index, and history of angina were found to be associated with access use in EUR and the US. However, after adjustment for these patient characteristics, large differences are still seen in AVF use between the US and EUR. Instead, a facility's preference for type of access [15] , and approach to vascular access and nephrologic care appear to be important factors determining access placement. For example, early nephrologic care is similar in the US and EUR, with 84% of EUR patients seeing a nephrologist Ͼ30 days prior to ESRD compared to 74% of US patients. Despite this similarity, the percentage of US patients starting HD with a permanent access is nearly one-half that of patients in EUR. In addition, for new patients receiving nephrologic care for Ͼ30 days prior to ESRD, the percentage starting HD with a permanent access was 79% in EUR compared with 48% in the US. This large difference exists despite the US practice of placing more grafts tients using a permanent vascular access for their first HD treatment [16] .
The large difference between EUR and the US in the proportion of incident patients starting HD with a per-US from 54% (95% CI 43 to 64%) in 1996 to 28% (95% manent access suggests that in the US there may be (1) CI 23 to 34%) in year 2000 (P Ͻ 0.01).
overall decreased priority during the pre-ESRD period for establishing a permanent access that can function for DISCUSSION a patient's first HD session, (2) more difficulties encountered from a surgical or technical standpoint in creating The direct comparison of vascular access use provided a vascular access that successfully matures so as to be by DOPPS indicates large differences in vascular access functional for the start of HD, (3) greater time/adminisuse in EUR compared with the US. EUR vascular access trative constraints or patient reluctance, hindering early placement is centered around AVF use with 66% of new placement of permanent accesses, or (4) more frequent ESRD patients starting HD with an AVF, and AVF use failure of pre-ESRD evaluations to accurately estimate rising to 80% in EUR for all HD patients. Subgroup onset of ESRD, leading to a delay in referral for vascular analyses demonstrate that EUR practice is successful in access placement. The net result of the current US vascuplacing AVF at a high rate in a broad spectrum of palar access practice is that 46% of US patients start HD tients including older diabetic female patients with corowith a catheter and have not had a permanent vascular nary artery disease and/or peripheral vascular disease.
access created prior to starting HD. This failure to place Only 2% of EUR incident patients initiate HD with a a permanent access during the pre-ESRD period occurs graft, indicating that grafts are seldom chosen for a padespite 55% of these patients without a permanent actient's first permanent access in EUR.
cess having seen a nephrologist Ͼ30 days prior to ESRD. In contrast to EUR, grafts are the predominant perma-
The problem of incident patients starting HD without a nent access in the US, serving 58% of prevalent patients, permanent access placed during the pre-ESRD period and used by 24% of incident patients when starting HD.
is not limited to the US. In EUR, approximately 25% AVF are used by only 15% of US incident patients at of incident patients start HD with a temporary access and initiation of HD, with AVF use increasing to 24% among have not had a permanent access placed prior to ESRD. For this group of patients, 56% had seen a nephrologist prevalent patients in the US. These results from DOPPS Ͼ30 days prior to ESRD. Both in the US and EUR, forming pre-operative vascular mapping with greater use of brachiocephalic upper arm AVF [19, [21] [22] [23] , and utifurther gains may be made in starting patients with a permanent vascular access if a better understanding can lizing forearm superficial venous transposition [24] . Notably, Dr. Konner has achieved high levels of AVF use be gained regarding the obstacles and factors that result in patients not receiving a permanent access during the for a diverse patient population by performing detailed mapping of patient vasculature prior to AVF placement, pre-ESRD period even though a nephrologist is seen more than 30 days prior to ESRD. and employing a variety of different surgical approaches to address the challenges posed by different clinical and An important aspect of new ESRD patients starting HD with a permanent access is the process and organizaanatomical presentations [25, 26] . A noteworthy observation during the analysis of AVF tional structure of the referral network for placing vascular accesses. An expedient process of Յ2 weeks from time versus graft use among new HD patients in EUR and the US was the finding that the likelihood of AVF use of referral until access placement was associated with a 1.8-fold higher likelihood of new ESRD patients beginwas 40% lower in dialysis units in which surgery trainees either assisted or performed permanent vascular access ning HD with a permanent vascular access. The number of surgeons placing permanent accesses for a facility or placements (Table 5) . Surgery trainees are used in approximately 34% of DOPPS dialysis units in both the whether AVF cannulation typically occurs within two months from the date of access creation, however, did US and EUR. These results suggest that graft placement may be emphasized to a greater extent in surgical trainnot appear to be associated with whether incident patients began dialysis with a permanent access.
ing settings or that trainees are not adequately prepared to create functioning AVF in a diverse patient populaPreviously, Hirth et al showed that AVF versus graft use in the US strongly differed across some geographic tion. This may represent an opportunity for intervention and improved vascular access outcomes for patients at regions and according to patient socioeconomic status [17] . These analyses were adjusted for demographic and HD centers affiliated with surgical training programs. In the US, 60% of new ESRD patients begin HD with comorbid conditions, and suggested that factors beyond a patient's clinical presentation may play an important a catheter compared with 31% in EUR. One of the negative effects for patients starting HD with a temporole in access placement decisions. Economic factors appear not to be a strong driving force for high graft use rary access is revealed in comparing AVF survival in Figure 4 . These results indicate that AVF and graft surin the US as suggested by two reports in which the annual costs for use of grafts were found to be higher than for vival are substantially greater if used at the start of HD rather than after a patient begins dialysis with a catheter. AVF (abstract; Collins et al, J Am Soc Nephrol 10:203A, 1999) [18] . Furthermore, for most patients, costs for eiAlthough there may be patient characteristics not controlled for in the survival analysis that may contribute ther type of access are covered by Medicare, and the differences are small concerning reimbursements to phyto the access survival differences in Figure 4 , these results of greater AVF and graft failure after catheter use could sicians for placing grafts versus AVFs.
In the present study, a large variation of 0 to 100% also be due to (1) placement location of temporary catheters that adversely affect longevity of subsequently used AVF use was seen among different dialysis units in the US and EUR. AVF use in EUR facilities varied from AVF or grafts (abstract; Young et al, J Am Soc Nephrol 10:223A, 1999); (2) the AVF being used before they have 39% to 100%, with 31% of EUR facilities having Ն90% of their patients dialyzing with an AVF. In addition, fully matured [27] ; or (3) changes/losses in biological factors occurring once a patient begins hemodialysis with DOPPS data (not shown) and other reports indicate that four of the five EUR countries have a smaller percent these changes leading to less favorable access maturation resulting in higher access failure rates. of ESRD patients receiving peritoneal dialysis than in the US [9, 11] . Therefore, the higher rates of AVF use Similar to several other studies [20, [28] [29] [30] [31] [32] [33] , our results showed greater survival of AVF compared with grafts in EUR likely are not due to poor candidates for AVF being steered to peritoneal dialysis. The higher rates of in the US. Furthermore, AVF survival was found to be substantially better in EUR compared with the US AVF use seen in EUR suggest that in many EUR dialysis units a process of vascular access care is in place leading (RR ϭ 0.49, P ϭ 0.0005). The reasons for this latter effect will be evaluated in future analyses. to successful AVF placement in a very high proportion of patients. A key question for future examination, in During the past 12 years, several reports including the 1997 DOQI Guidelines have recommended that pracaddition to a strong commitment to AVF placement, is what processes have these dialysis units implemented in titioners avoid placing catheters in the subclavian vein to minimize central vein stenoses and other complications order to be highly successful in creating AVF for their patients? Some dialysis units have reported substantial that may prohibit future placement of vascular accesses on the side of the cannulation [2, 34-40]. Catheter placeincreases in AVF use through organizational changes in their approach to vascular access care [19, 20] , perment in the subclavian vein differed considerably be-
